Pfizer's surprise Remoxy withdrawal slashes Pain, Durect prices by half
This article was originally published in Scrip
Executive Summary
Pfizer has left its partner Pain Therapeutics shocked by an unexpected decision to withdraw from a deal between the two companies relating to opioid agonist Remoxy. Investors too were left reeling, sending shares of both Pain Therapeutics and Durect, the developer of the technology behind Remoxy, plummeting.
You may also be interested in...
PTI’s Remoxy: Negative FDA Panel Review May Be The End Of Abuse-Deterrent Opioid's Road
Concerns that the extended-release oxycodone product poses the same potential for intravenous abuse as Endo’s withdrawn Opana ER drive FDA advisory committee recommendation against approval, laying the groundwork for a fourth complete response letter; FDA’s comparison of Remoxy to Opana during the meeting ‘borders on slanderous,’ PTI CEO Barbier tells Scrip, predicting sponsors will be dissuaded by the shifting regulatory goalposts for abuse-deterrent formulations.
WuXi eases CAR-T manufacturing burden with new US plant
China's WuXi PharmaTech, an R&D technology company serving the pharmaceutical, biotechnology and medical device industries, has announced construction of a new manufacturing facility in Philadelphia, US designed for cell therapy products, including chimeric antigen receptor T-cell (CAR-T) therapies. More manufacturing power is crucial to the success of this burgeoning, high-potential field.
NICE lifts Entyvio restrictions after Takeda offers discount
Takeda has managed to persuade NICE, the health technology appraisal institute for England and Wales, to recommend its ulcerative colitis drug Entyvio (vedolizumab) without the restrictions the institute had previously stipulated – as long as the company offers a discount via a patient access scheme.